Great 1st day at #ESMO24 @myesmo.bsky.social

NKT2152 Ushers in a New Era of HIF-2α Inhibition in Pretreated Advanced ccRCC Toni Choueiri, MD, discusses the unique features of NKT2152, the agent’s safety profile in RCC, and future research directions across GU oncology.

NKT2152 Ushers in a New Era of HIF-2α Inhibition in Pretreated Advanced ccRCC
@drchoueiri.bsky.social @danafarbernews.bsky.social #ESMO24 #kcsm #oncology
www.onclive.com/view/nkt2152...

TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC Toni Choueiri, MD, details the PFS outcomes and safety profiles for tivozanib plus nivolumab vs tivozanib alone in metastatic renal cell carcinoma

TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC @drchoueiri.bsky.social @danafarber.bsky.social #ESMO24 #kcsm #oncology www.onclive.com/view/tinivo-...

Retifanlimab Emerges as Potential New SOC in Advanced SCAC Sheela Rao, MBBS, MD, FRCP, discusses data from the phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab plus chemotherapy vs chemotherapy in advanced SCAC.

Retifanlimab Emerges as Potential New SOC in Advanced SCAC #oncology #ESMO24 www.onclive.com/view/retifan...

Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need Dr. Xiuning Le highlights real-world data on therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations, emphasizing the need for improved treatments, at ESMO Congress 2...

🔥@onclive.bsky.social🆙
✅Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations
🎯RWD based on @guardanthealth.bsky.social INFORM
👥Dr. Xiuning le
#LCSM @oncoalert.bsky.social #EGFR #ESMO24
www.onclive.com/view/real-wo...

Combination Regimens Make Their Mark in Frontline HCC In a Peer Exchange, HCC experts discussed how new data from the HIMALAYA, LEAP-012, EMERALD-1, and IMbrave050 trials could be used to optimize treatment.

Combination Regimens Make Their Mark in Frontline HCC @danengle.bsky.social #ESMO24 #oncology
www.onclive.com/view/combina...

The benchmark for $JANX's prostate cancer data release tomorrow is the STEAP1xCD3 results that $AMGN presented at #ESMO24

In summary:
- 53% PSA50, with 59% DOR at 3mo and 6% at 6mo
- 34% PSA90, 29% ORR, mRPFS 7.8mo
- 72% Gr3 AEs, 76% CRS, 69% musculoskeletal events

Biomarker testing in NSCLC: patient and caregiver awareness and understanding | COR2ED We are pleased to share findings from a PRECISION ONCOLOGY CONNECT survey that were presented as a poster at ESMO 2024.   A group of international

Proud to serve as co-PI of this global assessment of #NSCLC biomarker testing experiences among patients and caregivers, presented at #ESMO24 #LCSM cor2ed.com/precision-on...

#BLADDR24 #ESMO24 highlights
➡️ Adj CKI post cystectomy
➡️ SUNRISE IV - can neoadjuvant non-platinum treatment be used?
➡️ Trials of perioperative combos
@oncoalert.bsky.social

Final overall survival results from KEYNOTE-811 in HER2+ metastatic gastric cancer - VJOncology Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the final overall survival (OS) analysis of the...

November is gastric cancer awareness month and we are sharing updates in the field ⭐

At #ESMO24, we spoke with Filippo Pietrantonio on the final OS results from KEYNOTE-811 in HER2+ metastatic gastric cancer.

👉See the video below! 👈

https://buff.ly/4ezvhmz

#stcsm #gism

Did you miss out on #ESMO24 this year? No worries! This recent episode of CancerSpeak has you covered 📻 Topics include advances in melanoma, immunotherapy, and the role of social media in clinical oncology and patient advocacy. @oncoalert.bsky.social #OncSky

cancerspeak.podbean.com/e/key-highli...

Don’t you love it when the good ones get recognized!
👏Bravo, @viveksubbiah.bsky.social Subbiah, on being Clarivate Highly Cited Researcher! He blocks 30m after his talks to ensure he gets to discuss w every person who comes up to him after! Way to advance oncology drug development! 👏
📷 #ESMO24

Long-term survivorship concerns of patients with esophageal and gastric cancer - VJOncology Jessie Elliott, FRCS, PhD, Trinity St. James’s Cancer Institute, Dublin, Ireland, discusses the long-term survivorship concerns of patients with esophageal...

November is gastric cancer awareness month and we are sharing updates in the field ⭐

At #ESMO24, we spoke with Jessie Elliott on long-term survivorship concerns of patients with esophageal and gastric cancer.

👉See the video below! 👈

https://buff.ly/48WQh5R

#stcsm #gism

The Triple meeting is coming up this week in Barcelona. Second big oncology meeting in a row after #ESMO24. Some updates we’ll be following:

$RVMD KRAS
$IDYA MAT2A
$TYRA FGFR3
$ERAS BRAF/CRAF
Nested RAF/MEK glue
Aktis Nectin4

#BioSky

At #ESMO24 this week, Prof Christina B Yap presented 'How much do real world patients really differ from clinical trials?' in the session on How Real World Data (RWD) are transforming oncology.

#ESMO24 A summary of presentations that caught my eye:

- STX-478 inhibitor in PIK3CA mutant tumors
- BMS-986365 AR degrader/antagonist in mCRPC
- BNT327 PD-L1/VEGF in EGFR-mutated NSCLC
- NVL-655 inhibitor in ALK-mutated NSCLC
- Ponsegromab anti-GDF15 for cancer patients with cachexia

ESMO 2024 Le PIONeeR Project présente pour la première fois les résultats de son étude clinique de phase Ib/IIa. fr.ap-hm.fr/actu/esmo-20... #ESMO24 #PIONeeRProject #Oncologie #Immunothérapie #RechercheMédicale #NSCLC #CancerDuPoumon #InnovationSanté #Phase1b2a #EssaiClinique #RHU #Marseille

Fall makes for #FunTieFriday on #BowTieFriday. So much amazing science in #GIonc #PallOnc #SuppOnc happening at #ESMO24 this week. What puts color in your life?

@docwithbowtie.bsky.social
@ctsinclair.bsky.social
@engagetheo.bsky.social
@pinkprincess.bsky.social

CanSky MedSky hapc hpm

Chemotherapy still preferred over Pluvicto in 2L mCRPC. Pluvicto is the SOC after chemo $NVS
#ESMO24

Some competition for $RVMD at #ESMO24. Astellas' KRAS G12D degrader shows 33% ORR at the highest dose (n=12), with 42% in PDAC (n=7). Still low n, but as a reference $RVMD had a 27% ORR in Ras-mutant PDAC

It would be nice to build a biotech community on this site. In three weeks I’ll be attending #ESMO24 and I’ll post some content here. Let’s see if we can bring some coverage of the conference here

Tracking #MASCC24 and #ESMO24 updates along with planning for a #UK 🇬🇧 holiday next month has me grateful for our global 🌐 family on #BowTieFriday

@docwithbowtie.bsky.social
@ctsinclair.bsky.social
@engagetheo.bsky.social
@pinkprincess.bsky.social

CanSky MedSky hapc hpm